Suppliers and packagers for generic pharmaceutical drug: GLATIRAMER ACETATE

GLATIRAMER ACETATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622	NDA	Teva Neuroscience, Inc.	68546-317-30	30 BLISTER PACK in 1 CARTON (68546-317-30) / 1 SYRINGE, GLASS in 1 BLISTER PACK / 1 mL in 1 SYRINGE, GLASS	2008-04-28
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622	NDA	Teva Neuroscience, Inc.	68546-325-06	6 BLISTER PACK in 1 CARTON (68546-325-06) / 1 SYRINGE, GLASS in 1 BLISTER PACK / 1 mL in 1 SYRINGE, GLASS	2014-01-29
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622	NDA	Teva Neuroscience, Inc.	68546-325-12	12 BLISTER PACK in 1 CARTON (68546-325-12) / 1 SYRINGE, GLASS in 1 BLISTER PACK / 1 mL in 1 SYRINGE, GLASS	2014-01-29

Last updated: July 27, 2025

ppliers for the Pharmaceutical Drug: Glatiramer Acetate

Introduction
Glatiramer acetate, marketed under brand names such as Copaxone, is a cornerstone immunomodulatory therapy primarily used for managing relapsing forms of multiple sclerosis (MS). Since its initial approval by the U.S. Food and Drug Administration (FDA) in 1996, glatiramer acetate has fostered a competitive manufacturing landscape comprising several key suppliers globally. These suppliers are crucial for ensuring drug availability, fostering market competition, and driving innovation in MS treatment. This comprehensive analysis dissects the primary suppliers of glatiramer acetate, their manufacturing capacities, strategic partnerships, and implications for stakeholders.

---

Manufacturers of Glatiramer Acetate

1. Teva Pharmaceutical Industries Ltd.
Teva remains the dominant producer of glatiramer acetate globally, holding a significant market share since its introduction. The company's flagship product, Copaxone, has commanded widespread clinical use and robust sales. Teva’s manufacturing facilities are strategically located primarily in Israel, where they produce the branded formulation, as well as in the United States. The company's continuous investment in manufacturing capacity expansion and supply chain improvements solidifies its position as the leading supplier.

In recent developments, Teva has faced patent challenges and market erosion due to biosimilar competitors, yet it maintains a broad pipeline of formulations and versions to uphold its market share. The company's regulatory adherence and scale enable it to meet global demand efficiently.

2. Mylan (A Subsidiary of Viatris)
Mylan, now part of Viatris following a merger with Pfizer's Upjohn unit in 2020, was among the first competitors to develop biosimilar versions of glatiramer acetate. Its biosimilar, Glatiramer Acetate BCS (marketed as generics or biosimilars in multiple jurisdictions), aims to provide cost-effective options to healthcare systems and patients. Mylan's manufacturing facilities in Europe and the U.S. produce these biosimilar products, which have gained regulatory approvals in several markets.

The entry of biosimilars has significantly impacted the pricing dynamics of glatiramer acetate, increasing accessibility but challenging Teva’s dominance. Mylan/Viatris continues to invest in biosimilar development and capacity, positioning itself as a key player in this segment.

3. Samsung Bioepis
Samsung Bioepis emerged as the global leader in biosimilar development, including research into glatiramer acetate biosimilars. Its collaborations with major biopharmaceutical firms have enabled rapid development and registration of biosimilar candidates. Although not yet widely commercialized, Samsung Bioepis's pipeline may introduce additional competition, especially in markets emphasizing biosimilars' cost savings.

4. Sandoz (A Novartis Division)
Sandoz has invested in biosimilar development for multiple biologics, including glatiramer acetate. The company has obtained regulatory approvals in various markets for its biosimilar versions and continues to pursue expansion into new territories. Its manufacturing capabilities in Europe and North America support its global positioning.

5. Other Emerging and Regional Manufacturers
In addition to these major players, several regional companies in Asia and Europe have initiated biosimilar development programs. Companies such as Pixium Biosciences and Celltrion are exploring biosimilars for multiple immune-modulating agents, adding diversity to the supply landscape. Their entry could influence supply costs and access, especially as regulatory pathways for biosimilars become more streamlined globally.

---

Supply Chain and Manufacturing Considerations

• Regulatory Approvals: Compliance with stringent guidelines from agencies such as the FDA, EMA (European Medicines Agency), and PMDA (Japan Pharmaceuticals and Medical Devices Agency) is vital for manufacturing operations. Conducting rigorous clinical trials for biosimilar approval adds to the complexity.

• Manufacturing Capacity: Capacity expansion has been a strategic focus, with companies investing in bioreactors, purification units, and quality control infrastructure. Teva, for example, has increased capacity to meet rising demand and buffer against supply disruptions.

• Pricing and Market Dynamics: Biosimilar entry has led to substantial price reductions, fostering market competition. This has implications for suppliers' profitability and investment strategies, influencing decisions on capacity, R&D, and strategic partnerships.

• Logistics and Distribution: Due to the sensitive nature of biologics, cold-chain logistics play a critical role in ensuring drug integrity from manufacturing facilities to end-users worldwide.

---

Implications for Stakeholders

Market Patients and Healthcare Providers
A diverse supply landscape enhances accessibility, allows for insurance and formulary negotiations, and offers options at varying price points. However, disparities in biosimilar availability across regions can influence treatment choices.

Pharmaceutical Companies and Investors
The landscape presents opportunities regarding biosimilar development, strategic licensing, and supply chain optimization. Market entrants must navigate regulatory hurdles, investment costs, and intellectual property rights, especially considering patent litigations involving teva and biosimilar developers.

Regulatory Bodies
Ensuring quality, safety, and efficacy remains paramount. The proliferation of biosimilars demands clear frameworks for approval, interchangeability, and post-market surveillance to maintain patient trust and market stability.

---

Key Takeaways

• Dominant Supplier: Teva remains the primary global supplier of branded glatiramer acetate, leveraging extensive manufacturing infrastructure and a broad product portfolio.

• Biosimilar Market Entry: Mylan/Viatris, Samsung Bioepis, Sandoz, and regional manufacturers have developed biosimilar versions, fostering competitive pricing and enhanced access.

• Supply Chain Risks: Capacity constraints, regulatory hurdles, and logistics complexity require continuous strategic planning by manufacturers.

• Market Dynamics: The biosimilar landscape tempers prices and influences repayment and formulary decisions, impacting profitability for original manufacturers.

• Future Outlook: Ongoing biosimilar development and manufacturing capacity expansion will shape supply stability, cost structures, and patient access in the coming decade.

---

FAQs

Q1: Who are the main global suppliers of glatiramer acetate?
A1: The primary supplier is Teva Pharmaceutical Industries Ltd., with biosimilar providers such as Viatris (Mylan), Samsung Bioepis, and Sandoz entering the market through biosimilar development and approvals.

Q2: How does the biosimilar market affect the supply of glatiramer acetate?
A2: Biosimilars increase competition, generally lowering prices and improving access. They also diversify supply sources but may introduce supply variability depending on regulatory approvals and manufacturing capacity.

Q3: What regulatory challenges do biosimilar manufacturers face?
A3: Manufacturers must demonstrate biosimilarity through extensive analytical, preclinical, and clinical data, meet stringent quality standards, and gain approval from agencies such as the FDA, EMA, or PMDA.

Q4: Are there regional differences in glatiramer acetate supply?
A4: Yes. While Teva supplies globally, regional manufacturers and biosimilar producers may predominantly serve specific markets, influenced by local regulatory environments, patent laws, and market demand.

Q5: What is the future outlook for glatiramer acetate supply?
A5: The future involves increased biosimilar penetration, capacity expansion, and potential innovation in formulations. These developments aim to enhance affordability, supply stability, and treatment options for MS patients worldwide.

References
[1] U.S. Food and Drug Administration. Copaxone (glatiramer acetate) approval details.
[2] European Medicines Agency. Summary of product characteristics for glatiramer acetate.
[3] Teva Pharmaceutical Industries Ltd. Annual Reports and Investor Presentations.
[4] Viatris/Biosimilar Markets Analysis Reports.
[5] Sandoz Biosimilar Pipeline and Approvals Publications.